18:38 , Feb 15, 2019 |  BC Week In Review  |  Financial News

Anchiano prices $30.5M NASDAQ offering

Anchiano Therapeutics Ltd. (Tel Aviv:ANCN; NASDAQ:ANCN) raised $30.5 million via a listing of ADSs on NASDAQ. On Feb. 12, the gene therapy company priced 2.6 million ADSs at $11.50, giving it a valuation of $78.5...
18:28 , Feb 12, 2019 |  BC Extra  |  Financial News

Anchiano slips after NASDAQ offering

Anchiano Therapeutics Ltd. (Tel Aviv:ANCN; NASDAQ:ANCN) slipped $0.70 to $10.80 on NASDAQ on Tuesday after raising $30.5 million in a listing of ADSs. The gene therapy company priced 2.6 million ADSs at $11.50, giving it...
17:34 , Jan 11, 2019 |  BC Week In Review  |  Financial News

Alector, Poseida and Anchiano propose NASDAQ listings

Alector Inc. (South San Francisco, Calif.), Poseida Therapeutics Inc. (San Diego, Calif.) and Anchiano Therapeutics Inc. (Tel Aviv:ANCN) have proposed to list on NASDAQ. Alector, which aims to target immune dysfunction to treat neurodegenerative disorders,...
04:39 , Jan 8, 2019 |  BC Extra  |  Financial News

Alector, Poseida and Anchiano propose NASDAQ listings

Alector Inc. (South San Francisco, Calif.), Poseida Therapeutics Inc. (San Diego, Calif.) and Anchiano Therapeutics Inc. (Tel Aviv:ANCN) have proposed to list on NASDAQ. Alector, which aims to target immune dysfunction to treat neurodegenerative disorders,...
23:26 , Nov 13, 2018 |  BC Extra  |  Company News

Management tracks: Anchiano, ContraFect

Cancer company Anchiano Therapeutics Inc. (Tel Aviv:ANCN) appointed Stephen Hoffman chairman. He is CEO of Aerpio Pharmaceuticals Inc. (OTCQB:ARPO). Anchiano also named Robert Connelly a director. He was a venture partner at Flagship Pioneering and...
23:51 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Cell culture and mouse studies suggest Tregs or factors secreted by Tregs could help treat MI. In primary rat cardiomyocytes, supernatant derived from the media of primary rat Treg cultures increased...
22:28 , Mar 8, 2018 |  BC Extra  |  Company News

Management tracks: Takeda, Nimbus

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said CFO James Kehoe will step down, effective March 31. He is succeeded by the CFO of Takeda's Europe and Canada business unit, Costa Saroukos. Nimbus Therapeutics LLC (Cambridge, Mass.)...
17:28 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

BioCanCell reports Phase I/IIa data for BC-819 in bladder cancer

BioCanCell Ltd. (Tel Aviv:BICL) reported final data from a Phase I/IIa trial in 38 patients with resected, early stage non-muscle invasive bladder cancer (NMIBC) showing that BC-819 plus bacillus Calmette-Guérin (BCG) led to a 24-month...
22:49 , Jan 5, 2018 |  BC Week In Review  |  Company News

BioCanCell shareholders turn down offer to go private

BioCanCell Therapeutics Inc. (Tel Aviv:BICL) said its shareholders did not approve a full tender offer led by its largest shareholder Clal Biotechnology Industries Ltd. (Tel Aviv:CBI) to take BioCanCell private. According to BioCanCell, the offering...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

BC-819: Pilot trial data

A pilot trial in 38 intermediate- and high-risk bladder cancer patients showed that an alternating treatment regimen with BC-819 followed by bacillus Calmette-Guerin (BCG) once or twice weekly was safe with no severe treatment-related adverse...